Medical Director Fabrizio Calisti describes the fund, its foundation in the CNS but broad interest today, current portfolio holdings, and...

Managing Director Marco Baccanti explains how the foundation was created last year to boost the amount of IP and licensing that is...

Anders Bue Klein describes how the BI has made it easier for founders like him to take work from university and turn it into a company....

The former CEO of Prosensa and current contributor to numerous boards highlights the past and current successes that have made this region a

He shares his take on biotech and discusses Terns, Novo Nordisk, Corbus, Harmony Bio, IDEAYA, and Adverum.

He describes how Vedanta is isolating specific bacterial strains and using them as a defined composition for its medicines, and why he...

The VP of Lab Technologies at Aera Therapeutics describes what lab work was like before technology digitized and dramatically changed...

Gene Yeo describes the latest advances in RNA and discusses mRNA, RNAi, antisense, exon skipping and more.

General Partner Ross Barrett talks about how a new, larger fund will enable them to invest in more companies, and he shares some...

As a practicing clinician, Caroline Chung became increasingly focused on digital solutions. Today, she tells us how it is impacting...

Jeff Jones notes how radioisotopes are being added to more than just antibodies, and calls out upcoming data from Perspective...

He discusses pathways that could play a role in helping solve this problem, including combinations with ADCs, STING and CD47, and work by...

Matt Biegler summarizes a breast cancer panel from the conference and talks about recent data from Relay and upcoming data from Gilead....

She describes the properties that she believes give NK cells an edge over T-cells, and discussed work in cell therapies, engagers, and...

John Heymach gives an overview of how TKIs are progressing in the EGFR and HER2 space, his thoughts on the recent VEGF x PD1 data that...

Ferran Prat, who is in charge of external innovation at MD Anderson, talks about what makes for a good partnership, and he also describes...

Professor Lannfelt recounts the history of researching amyloid beta and explains why he thinks it is vital to target amyloid beta...

Chris Molineaux kicks off this annual meeting of the Pennsylvania life sciences ecosystem and highlights this year's partnering theme.

He introduces us to Pareto and the conference, and highlights BioInvent, Oculis, Camurus, Vicore Pharma, and Calliditas.

He describes keys such as having a U.S. listing, keeping powerpoint presentations concise, and following the actions of a peer group.